15th Apr 2026 07:00
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
EMI Share Option Scheme
York, U.K. 15 April 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that it has allocated a total of 3,096,000 shares options under its pre-existing EMI share option scheme to be provided to all UK based staff who have been employed by the company for 12 months or more.
Shares to a total of 1,548,000 shares will be allocated in April 2026 with an additional 1,548,000 to be allocated in April 2027. Shares will be exercisable at nil cost 3 years post allocation.
The total number of EMI option shares being allocated as described above is 3,096,000 shares or 1.23% of total issued shares.
Abingdon Health plc | www.abingdonhealth.com/investors/ | ||
Chris Hand, Executive Chairman
| Via Walbrook PR | ||
Tom Hayes, CFO
| |||
Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 7220 0500 | ||
Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance) Nigel Birks (Life Science Specialist Sales) | |||
Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or [email protected] | ||
Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
About Abingdon Health
Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.
The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.
Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.
Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com.
LEI - 213800XFI4WV3FBILO20
Related Shares:
Abingdon Healt.